TrialDrugs in R&D2019

Impact of Primary Tumour Location and Early Tumour Shrinkage on Outcomes in Patients with RAS Wild-Type Metastatic Colorectal Cancer Following First-Line FOLFIRI Plus Panitumumab.

Claus-Henning Köhne et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.